Published in final edited form as:

Clin Gastroenterol Hepatol. 2014 April ; 12(4): 632–635. doi:10.1016/j.cgh.2013.10.031.

The Unfolding Story of Celiac Disease Risk Factors

Benjamin Lebwohl, MD, MS^{1,2,*}, Jonas F. Ludvigsson, MD, PhD^{3,4}, and Peter H.R. Green, MD¹

¹Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA

² Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA

³Medical Epidemiology and Biostatistics Unit, Karolinska Institutet, Stockholm, Sweden

⁴ Department of Pediatrics, Örebro University Hospital, Sweden

What causes celiac disease? On the surface, the answer is straightforward: dietary gluten. In susceptible individuals, ingested gluten is deamidated by tissue transglutaminase in the lamina propria of the small intestine and then bound by antigen presenting cells to the Human Leukocyte Antigen (HLA) DQ2 or DQ8. This sets off an immune cascade that results in infiltration of the epithelium with lymphocytes and tissue destruction, leading to villous atrophy that is characteristic of celiac disease.¹

The identification of dietary gluten as the environmental culprit was a major advance in the history of gastroenterology. Though diet was long considered to trigger or exacerbate celiac disease, it was the Dutch pediatrician Willem Dicke who determined it was the protein fraction of wheat that made his patients ill. These observations were made prior to World War II, and Dicke's hypothesis was borne out during a blockade-induced famine in 1944, when patients with celiac disease improved markedly during the period of severe wheat shortage, only to relapse upon the reintroduction of wheat at the end of the famine.² The subsequent discovery that the HLA DQ2 or DQ8 haplotype was necessary for the development of celiac disease³ led to our present understanding that celiac disease arises when gluten is introduced to the genetically susceptible individual.

Yet this simple explanation is belied by the fact this gene-environment combination is far more common than the prevalence of celiac disease; gluten is a ubiquitous dietary staple, and the at-risk HLA haplotypes are present in 30-40% of western populations.⁴ Genome wide association studies have identified dozens of additional genetic risk loci relating to the immune response, illustrating that celiac disease is a complex, polygenic immune-based disorder.^{5,6} But just as the genetic story of celiac disease is more complicated than HLA inheritance, the environmental trigger of celiac disease is about more than gluten. Ultimately, our growing knowledge of the genetic determinants of celiac disease will by itself not be adequate to understand why celiac disease develops. Epidemics are triggered by

© 2013 The American Gastroenterological Association. Published by Elsevier Inc. All rights reserved.

*Correspondence and reprint requests: Benjamin Lebwohl, MD, MS The Celiac Disease Center at Columbia University 180 Fort Washington Avenue, Suite 936 New York, NY 10032 Phone: 212-305-5590 Fax: 212-305-3738 BL114@columbia.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Potential conflicts of interest: None

environmental exposures, since genetic changes are too slow to drive these phenomena. We have now witnessed two epidemics of celiac disease: one that was dramatic and limited, and another that, while less visible, is greater in scale and ongoing.

The Swedish epidemic of celiac disease of 1985-1994 has been extensively documented, and resulted in the development of hypotheses regarding environmental risk factors for this disorder.⁷ This epidemic was restricted to children younger than two years; in that age group, the incidence of diagnosed celiac disease rose from 65 cases per 100,000 person-years to 198 cases per 100,000 person-years. In contrast, incidence data for older children were relatively flat during this period. The epidemic abruptly ended in 1995, though children born during the period of the epidemic have an ongoing increased risk of developing celiac disease. Subsequent investigation led to the hypothesis that infant feeding practices affect the risk of celiac disease in young children. The epidemic occurred during a period of relatively low rates of breastfeeding at the age of 6 months and during the same period of time, the quantity of gluten in infant formula greatly increased. While it is difficult to separate the relative importance of each feeding practice, it appeared that high quantity of initial gluten intake without overlapping with breastfeeding was responsible for this epidemic. Although a systematic review of the issue has concluded that breastfeeding has not been definitively proven to be associated with risk of celiac disease,⁸ subsequent research has indicated that the timing of gluten introduction is important in determining risk.⁹ PreventCD, a prospective randomized trial of infants with a family history of celiac disease, is testing specifically whether the introduction of small quantities of gluten beginning at age 4 months of age will induce tolerance to gluten in this high-risk group.¹⁰

The second epidemic is more diffusely spread over time and space. Studies from the United States and elsewhere have shown that the seroprevalence of CD (as defined by positive tissue transglutaminase and endomysial antibodies) has increased markedly in recent decades. An analysis of stored serum from military recruits at the Warren Air Force Base in the years spanning 1948-1954 found a celiac disease seroprevalence of 0.2%, while two recent cohorts from Olmsted County (spanning the years 2006-2008) matched by year of birth and age at sampling found a seroprevalence of 0.9% and 0.8%, respectively.¹¹ An analysis of another cohort in this country found a doubling in seroprevalence during adulthood from 1974 (0.21%) to 1989 (0.45%).¹² The mode of presentation of CD has changed in the past generation, with rising numbers of patients presenting without diarrhea.¹³ Patients presenting with anemia may have more severe disease expression (as measured by the degree of villous atrophy and the presence of metabolic bone disease) than patients presenting with diarrhea.¹⁴ Since most individuals in the United States with celiac disease are undiagnosed,¹⁵ this is largely a hidden epidemic, but there is no reason to believe that the prevalence has peaked. In Finland, which had a higher prevalence of celiac disease than the United States to begin with, the seroprevalence of celiac disease doubled between the years 1978 (1.05%) and 2000 (1.99%).¹⁶ We do not know whether this epidemic will subside or if the prevalence of celiac disease will continue to rise to a new set-point. But given the morbidity associated with celiac disease¹⁷ and the cost and difficulty of the gluten-free diet^{18,19} these data have sparked interest in identifying the cause of this less visible epidemic.

Certain infections (such as rotavirus among infants²⁰ and *Campylobacter* among adults²¹) have recently been shown to be associated with a increased risk of celiac disease, but rates of these infections have not increased markedly, and so are not likely to be driving this epidemic. In contrast, a *lack* of exposure to certain microbes is a hallmark of modern times, and the increase in celiac disease is congruent with the hygiene hypothesis, which states that decreased exposure to microbes may be driving the rise in autoimmune and atopic conditions. This hypothesis is particularly compelling in light of a recent study that found a

dramatically different seroprevalence of celiac disease in Finland (1.4%) and the Russian Karelia (0.6%), geographically proximate areas with a similar prevalence of HLA DQ2 and DQ8, but with major differences in economic development.²²

Further evidence implicating our modern relationship with microbes is now accumulating. Children who were born via elective Caesarian section are at increased risk of developing celiac disease, while those born via emergent Caesarian section (and may have had contact with the birth canal) are not.²³ In addition, there appears to be an inverse relationship between *Helicobacter pylori* colonization and celiac disease.²⁴ Drugs are another modern innovation that may be affecting the celiac disease epidemic. Population-based studies from Sweden have shown that prescription of antibiotics²⁵ and proton pump inhibitors²⁶ are each associated with an increased risk of the subsequent development of celiac disease.

The associations identified in these studies are not necessarily causal. Studies of drug exposure in particular may be prone to protopathic bias, wherein early symptoms of the outcome of interest (celiac disease) may lead to the prescription of the exposure (e.g. antibiotics or proton pump inhibitors).²⁷ Confounding variables, such as another (unmeasured) microbe that correlates positively with *Helicobacter pylori* and is protective against celiac disease, would create a correlation of this exposure and outcome without direct causation. While methodological measures can be taken to address bias and confounding, ultimately these studies should be viewed as hypothesis-generating, mandating investigation to test the potential mechanisms by which exposures inherent to modern life may be contributing to this immune-based disorder.

What about other medications, such as supplements? In this month's issue of *Clinical Gastroenterology and Hepatology*, Størdal and colleagues report on an association between maternal iron supplementation among pregnant women and the risk of the subsequent diagnosis of celiac disease in their offspring.²⁸ The authors found that the use of iron, whether as sole supplements or in combination in a multivitamin/mineral product, is associated with an increased risk of celiac disease (OR 1.48), which remained significant after adjusting for maternal celiac disease, gender of the child, age of the child, and the timing of gluten introduction.

This is a methodologically rigorous study and the findings are intriguing. Strengths include its prospective design, in which exposure was measured prior to outcome, the large cohort size, long follow-up period, and the use of validated food frequency questionnaires to measure dietary iron. A significant limitation is the reliance on a combination of parental reporting and non-validated method of using the Norwegian Patient Register for case identification. To compensate for this, the investigators performed a sensitivity analysis in which 10% and 20% of cases were re-classified as controls, and found that the association between iron supplementation and celiac disease persisted. This is reassuring, provided that misclassification due to reliance on claims codes was random, and not differential. While health-conscious behavior may be associated with iron supplement use and a celiac disease diagnosis, the association between exposure and outcome was seen only in iron supplements and not for other dietary supplements. The finding of a dose-response relationship between estimated cumulative iron supplementation and the subsequent risk of celiac disease also argues for causality.

The mechanism by which iron supplementation could increase the risk of celiac disease is uncertain, but there are a few promising leads. Proteins related to iron metabolism including hepcidin and lactoferrin influence innate immunity,²⁹ and the host's iron status may influence the makeup of the microbiome.^{30,31} The notion that excess iron may lead to a loss of immune tolerance has precedent; a population-based case-control study found a greater

than 2-fold risk of celiac disease among individuals with hereditary hemochromatosis.³² A clear mechanism remains elusive at this time, especially since it is not established that exposure to increased iron *in utero* has downstream consequences on the development of the immune system after birth.

However, it cannot be ruled out that the association between iron supplementation and celiac disease is correlative but not causal. One important unmeasured confounding variable is undiagnosed maternal celiac disease, which may be associated with both the exposure (iron supplementation) and is certainly associated with the outcome (increased risk of celiac disease in the offspring). Anemia is strongly associated with undiagnosed celiac disease.³³ In a population where approximately 10% of women had anemia, assuming that 3% of such individuals anemia have undiagnosed celiac disease³³ (compared to a general population rate of 1%), and that 10% of these mothers' children would develop celiac disease, an association between iron supplementation and celiac disease would be observed, with a Odds Ratio of 1.27, which is similar in magnitude to the effect shown in this study. One way to examine the potential role of undiagnosed celiac disease in women with anemia would be to analyze maternal iron supplementation only in women without a diagnosis of anemia to see if the association with offspring CD would remain.

Given the uncertainty regarding causality, it is premature to argue that iron supplementation during pregnancy should be avoided in individuals with celiac disease whose offspring are at risk for developing this condition. Overall, while statistically significant and intriguing, the observed effect (an absolute risk increase of 0.15%) is modest in magnitude. This exposure is not driving the slow, ongoing epidemic of celiac disease. But the signal uncovered by this study may uncover the mechanisms by which many more have been losing immune tolerance of gluten in recent years.

Acknowledgments

Funding: Dr. Lebwohl is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number KL2 TR000081.

References

1. Kupfer SS, Jabri B. Pathophysiology of celiac disease. *Gastrointest Endosc Clin N Am*. 2012; 22:639–60. [PubMed: 23083984]
2. Dicke WK, Weijers HA, Van De Kamer JH. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. *Acta Paediatr*. 1953; 42:34–42. [PubMed: 13050382]
3. Sollid LM, Lie BA. Celiac disease genetics: current concepts and practical applications. *Clin Gastroenterol Hepatol*. 2005; 3:843–51. [PubMed: 16234020]
4. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. *J Clin Invest*. 2007; 117:41–9. [PubMed: 17200705]
5. van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. *Nat Genet*. 2007; 39:827–9. [PubMed: 17558408]
6. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. *Nat Genet*. 2011; 43:1193–201. [PubMed: 22057235]
7. Ivarsson A, Persson LA, Nystrom L, et al. Epidemic of coeliac disease in Swedish children. *Acta Paediatr*. 2000; 89:165–71. [PubMed: 10709885]
8. Szajewska H, Chmielewska A, Piescik-Lech M, et al. Systematic review: early infant feeding and the prevention of coeliac disease. *Aliment Pharmacol Ther*. 2012; 36:607–18. [PubMed: 22905651]

9. Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. *JAMA*. 2005; 293:2343–51. [PubMed: 15900004]
10. Hogen Esch CE, Rosen A, Auricchio R, et al. The PreventCD Study design: towards new strategies for the prevention of coeliac disease. *Eur J Gastroenterol Hepatol*. 2010; 22:1424–30. [PubMed: 21389794]
11. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. *Gastroenterology*. 2009; 137:88–93. [PubMed: 19362553]
12. Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. *Ann Med*. 2010; 42:530–8. [PubMed: 20868314]
13. Lo W, Sano K, Lebwohl B, Diamond B, Green PH. Changing presentation of adult celiac disease. *Dig Dis Sci*. 2003; 48:395–8. [PubMed: 12643621]
14. Abu Daya H, Lebwohl B, Lewis SK, Green PH. Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. *Clin Gastroenterol Hepatol*. 2013; 11:1472–7. [PubMed: 23756221]
15. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. *Am J Gastroenterol*. 2012; 107:1538–44. [PubMed: 22850429]
16. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. *Aliment Pharmacol Ther*. 2007; 26:1217–25. [PubMed: 17944736]
17. Green PH, Cellier C. Celiac disease. *N Engl J Med*. 2007; 357:1731–43. [PubMed: 17960014]
18. Lee AR, Ng DL, Zivin J, Green PH. Economic burden of a gluten-free diet. *J Hum Nutr Diet*. 2007; 20:423–30. [PubMed: 17845376]
19. Dorn SD, Hernandez L, Minaya MT, et al. The development and validation of a new coeliac disease quality of life survey (CD-QOL). *Aliment Pharmacol Ther*. 2010; 31:666–75. [PubMed: 20015103]
20. Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. *Am J Gastroenterol*. 2006; 101:2333–40. [PubMed: 17032199]
21. Riddle MS, Murray JA, Cash BD, Pimentel M, Porter CK. Pathogen-Specific Risk of Celiac Disease Following Bacterial Causes of Foodborne Illness: A Retrospective Cohort Study. *Dig Dis Sci*. 2013 in press.
22. Kondrashova A, Mustalahti K, Kaukinen K, et al. Lower economic status and inferior hygienic environment may protect against celiac disease. *Ann Med*. 2008; 40:223–31. [PubMed: 18382888]
23. Marild K, Stephansson O, Montgomery S, Murray JA, Ludvigsson JF. Pregnancy outcome and risk of celiac disease in offspring: a nationwide case-control study. *Gastroenterology*. 2012; 142:39–45. e3. [PubMed: 21995948]
24. Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with *Helicobacter pylori* colonization. *Am J Epidemiol*. 2013 in press.
25. Marild K, Ye W, Lebwohl B, et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. *BMC Gastroenterol*. 2013; 13:109. [PubMed: 23834758]
26. Lebwohl B, Spechler SJ, Wang TC, Green PH, Ludvigsson JF. Use of Proton Pump Inhibitors and Subsequent Risk of Celiac Disease. *Dig Liver Dis*. 2013 in press.
27. Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. *Am J Med*. 1980; 68:255–8. [PubMed: 7355896]
28. Størdal K, Haugen M, Brantsaeter AL, Lundin KE, Stene LC. Maternal iron supplement intake during pregnancy and risk of celiac disease in children. *Clin Gastroenterol Hepatol*. 2013 in press.
29. Johnson EE, Wessling-Resnick M. Iron metabolism and the innate immune response to infection. *Microbes Infect*. 2012; 14:207–16. [PubMed: 22033148]
30. Nairz M, Schroll A, Sonnweber T, Weiss G. The struggle for iron - a metal at the host-pathogen interface. *Cell Microbiol*. 2010; 12:1691–702. [PubMed: 20964797]
31. Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. *Am J Clin Nutr*. 2010; 92:1406–15. [PubMed: 20962160]

32. Ludvigsson JF, Murray JA, Adams PC, Elmberg M. Does hemochromatosis predispose to celiac disease? A study of 29,096 celiac disease patients. *Scand J Gastroenterol.* 2013; 48:176–82. [PubMed: 23256862]
33. Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. *Blood.* 2007; 109:412–21. [PubMed: 16973955]